Ulcer Monitoring in Diabetes Mellitus (Telesaar)

June 4, 2013 updated by: Johnny Froekjaer

Impact Assessment by Introducing Telemedicine Consultations for Treatment of Diabetic Patients With Foot Ulcers in Region of Southern Denmark - Randomized Prospective Study

Telemedicine technology enables a direct and online text- and image communication in the treatment system from patient to the ulcer specialist. The technology is expected to have patient-related, economic and therapeutic benefits. The study is a substudy of a larger project entitled "Renewing Health", where also the economic and management aspects are highlighted. However, only few randomized prospective studies are conducted in this field. The purpose of the study is in a randomized prospective study, to assess the impact of the introduction of the telemedicine technology as consultation form between ulcer-nurses in the primary sector and the wound clinics at the hospitals in the region. It is assessed whether the technology can be adopted without incurring the patient a risk. The study aims to perform an impact analysis of the introduction of new technologies for telemedicine wound monitoring in the treatment of diabetic foot ulcers through different studies.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Through randomized and prospective studies the project will show whether a telemedicine approach to wound care can be used as an alternative to traditional attendance at a wound clinic and document whether this consultation form provides a greater patient-satisfaction and cost savings. The project will document that telemedicine is equivalent to conventional outpatient attendance from a therapeutic aspect in terms of number of hospitalizations, number of extra controls, acute interventions and wound healing.

The project is also investigating the extent of time spent on the personnel side using telemedicine consultations compared with conventional outpatient appearances.

Study Type

Interventional

Enrollment (Anticipated)

400

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
    • Region of Southern Denmark
      • Esbjerg, Region of Southern Denmark, Denmark, 6700
        • Recruiting
        • South-west Hospital
      • Kolding, Region of Southern Denmark, Denmark, 6000
        • Recruiting
        • Lillebaelt Hospital
      • Odense, Region of Southern Denmark, Denmark, 5000
        • Recruiting
        • Odense University Hospital
      • Soenderborg, Region of Southern Denmark, Denmark, 6400
        • Recruiting
        • Hospital South Jutland
      • Svendborg, Region of Southern Denmark, Denmark, 5700
        • Recruiting
        • Svendborg Hospital
      • Vejle, Region of Southern Denmark, Denmark, 7100
        • Recruiting
        • Hospital Lillebaelt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Having diabetic foot ulcer
  • Referred for out-patient clinic treatment by general practitioner
  • Referred for out-patient clinic treatment by a surgical department
  • Living in Region of Southern Denmark

Exclusion Criteria:

  • Psychiatric disorder
  • Dementia
  • Chronic alcohol abuse which can affect compliance
  • Other disorder then diabetes mellitus that have caused foot ulcer (rheumatoid arthritis or arthritis urica)
  • Serious kidney disease which requires dialysis
  • Previous foot ulcer - which was part of the study
  • Expected healing within 2-4 weeks where only one control (final) is expected

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Control group. Regular treatment.
Experimental: Diabetes ulcer monitoring
Receives a telemedicine intervention: Diabetes ulcer monitoring.
Procedure: telemedicine consultations
Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
Other Names:
  • pleje.net

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Admissions to hospital
Time Frame: from time of inclusion until treatment completed, assessed up to 52 weeks
The number of admissions, incl, beddays, to hospital relating to ulcer treatment for each randomised patient during the treatment period.
from time of inclusion until treatment completed, assessed up to 52 weeks
Surgical procedures
Time Frame: from time of inclusion until completed treatment, assessed up to 52 weeks
The number of surgical procedures (incl. amputations) performed at hospital in realtion to the ulcer during the treatment period.
from time of inclusion until completed treatment, assessed up to 52 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ulcer healing
Time Frame: Progress is measured at minimum every 4 weeks during treatment period, assessed up to 52 weeks
The time from inclusion and start of treatment until ulcer is healed and treatment is stopped.
Progress is measured at minimum every 4 weeks during treatment period, assessed up to 52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Johnny Froekjaer

Collaborators

European Commission
Region of Southern Denmark

Investigators

  • Study Director: Benjamin S. Rasmussen, MD, Odense University Hospital
  • Principal Investigator: Johnny Froekjaer, MD, Odense University Hospital
  • Study Chair: Knud B. Yderstraede, MD, Odense University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2011

Primary Completion (Anticipated)

June 1, 2013

Study Completion (Anticipated)

November 1, 2013

Study Registration Dates

First Submitted

May 24, 2012

First Submitted That Met QC Criteria

May 28, 2012

First Posted (Estimate)

May 31, 2012

Study Record Updates

Last Update Posted (Estimate)

June 5, 2013

Last Update Submitted That Met QC Criteria

June 4, 2013

Last Verified

June 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Telesaar RH_3

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Clinical Trials on telemedicine consultations

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe